about
Fibroblast growth factor receptor 4: a putative key driver for the aggressive phenotype of hepatocellular carcinoma.O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies.Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas.Malignant Phenotypes in Metastatic Melanoma are Governed by SR-BI and its Association with Glycosylation and STAT5 Activation.Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma.Pharmacologic inhibition of STAT5 in acute myeloid leukemia.Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancerThe ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor DiseasePreloading with L-BPA, L-tyrosine and L-DOPA enhances the uptake of [ 18 F]FBPA in human and mouse tumour cell linesEmerging Epigenetic Therapeutic Targets in Acute Myeloid LeukemiaPre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemiaHigh activation of STAT5A drives peripheral T-cell lymphoma and leukemiaSTAT5 is Expressed in CD34+/CD38- Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms
P50
Q38974755-91DC20CD-F196-4100-984B-BF68BD91E7EAQ39028183-DA18D8C7-C4E1-4746-81C5-114CC7972E80Q47133172-8BC674F1-1F88-4CFB-B5CB-962C1C2A3640Q47703891-590E453E-8D04-4F95-949D-A3966A94A1C6Q48104415-04499C03-8FAE-40B1-B998-C7B4B9E4C64DQ48291629-628F51E6-E106-4BB6-8563-963D484B7B54Q52689082-FC212F2D-96AB-404B-95F0-A00E8DE2480EQ57174076-66B9E434-279E-4F3D-9A64-1A848E313816Q57340011-F8B6A95D-86B1-4206-A0B7-04FE00929325Q59726120-3F3CD1E0-911F-4ABE-BAB1-BF11625DAD1CQ90266900-D2B9361E-1170-4B05-88AD-21673052C147Q91526759-B119EA6E-8522-40F3-8DB3-8A5491E974FEQ92253988-9C8C5EC5-1F45-4CEB-9EED-584C9A4CEBA5Q93188811-F24AB4D1-3860-4886-8539-CCA3B051F154
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Bettina Wingelhofer
@ast
Bettina Wingelhofer
@en
Bettina Wingelhofer
@es
Bettina Wingelhofer
@nl
type
label
Bettina Wingelhofer
@ast
Bettina Wingelhofer
@en
Bettina Wingelhofer
@es
Bettina Wingelhofer
@nl
prefLabel
Bettina Wingelhofer
@ast
Bettina Wingelhofer
@en
Bettina Wingelhofer
@es
Bettina Wingelhofer
@nl
P106
P1153
56627013100
P31
P496
0000-0001-6108-5245